Population Pharmacokinetics of Amikacin Administered Once Daily in Patients with Different Renal Functions-Reference-Cited by-同舟云学术

Population Pharmacokinetics of Amikacin Administered Once Daily in Patients with Different Renal Functions

Published:2020-04-21 Issue:5 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Aréchiga-Alvarado Norma A.¹,Medellín-Garibay Susanna E.¹^ORCID,Milán-Segovia Rosa del C.¹^ORCID,Ortiz-Álvarez Arturo²,Magaña-Aquino Martín²,Romano-Moreno Silvia¹^ORCID

Affiliation:

1. Departamento de Farmacia y Tecnología de Medicamentos, Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico

2. Hospital Central Dr. Ignacio Morones Prieto, San Luis Potosí, Mexico

Abstract

The aim of this work was to evaluate the pharmacokinetics of amikacin in Mexican patients with different renal functions receiving once-daily dosing regimens and the influence of clinical and demographical covariates that may influence the optimization of this antibiotic. A prospective study was performed in a total of 63 patients with at least one determination of amikacin plasma concentration. Population pharmacokinetic (PK) parameters were estimated by nonlinear mixed-effects modeling; validations were performed for dosing recommendation purposes based on PK/pharmacodynamic simulations.

Funder

Consejo Nacional de Ciencia y Tecnología

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02178-19

Reference34 articles.

1. The postantibiotic effect of amikacin alone and in combination with piperacillin on gram-negative bacteria;Isaksson B;Scand J Infect Dis Suppl,1990

2. Clinical Response to Aminoglycoside Therapy: Importance of the Ratio of Peak Concentration to Minimal Inhibitory Concentration

3. Optimizing Aminoglycoside Therapy for Nosocomial Pneumonia Caused by Gram-Negative Bacteria

4. Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg/kg total body weight regimen

5. Amikacin in Critically Ill Patients: A Review of Population Pharmacokinetic Studies

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Individualized antibiotic dosage regimens for patients with augmented renal clearance;Frontiers in Pharmacology;2023-07-26

2. Failure to predict amikacin elimination in critically ill patients with cancer based on the estimated glomerular filtration rate: applying PBPK approach in a therapeutic drug monitoring study;European Journal of Clinical Pharmacology;2023-05-31

3. Amikacin pharmacokinetics in elderly patients with severe infections;European Journal of Pharmaceutical Sciences;2022-08

4. Drug Dosing in Critically Ill Adult Patients with Augmented Renal Clearance;European Journal of Drug Metabolism and Pharmacokinetics;2022-06-28

5. Prevalence and Risk Factors of Augmented Renal Clearance: A Systematic Review and Meta-Analysis;Pharmaceutics;2022-02-19